A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: RXi Pharmaceuticals, Corp.

Criteria

Inclusion Criteria:

• Adults, 21-55 years of age in general good health

• Previous partial hysterectomy, Cesarean section or abdominoplasty surgery resulting in a transverse hypertrophic scar of ≥ 11 cm in length

• Scar to be revised must have been present for > 9 months

Exclusion Criteria:

• Use of tobacco or nicotine-containing products

• Pregnant or lactating

• Post-menopausal or full hysterectomy